Curis Inc (CRIS):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10065)
◆英語タイトル:Curis Inc (CRIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10065
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating human cancers with substantial unmet medical need. It has three drug candidates in development, CUDC-907 for diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; and CA-4948 for advanced non-Hodgkin lymphomas. The company in collaboration with Genentech (a member of the Roche group) has developed Erivedge (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor. Erivedgeis approved for the treatment of advanced basal cell carcinoma (BCC). Curis is headquartered in Lexington, Massachusetts, the US.

Curis Inc (CRIS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Curis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Curis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Aurigene Discovery Enters into Agreement with Curis 10
Licensing Agreements 12
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 12
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 14
Curis Enters into License Agreement with Guangzhou BeBetter Medicine 15
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 16
Equity Offering 17
Curis Plans to Raise up to USD200 Million in Public Offering of Shares 17
Curis Plans to Raise up to USD23.6 Million in Public Offering of Shares 18
Curis Raises USD37 Million in Public Offering of Shares 19
Curis Raises USD69 Million in Public Offering of Shares 21
Curis Completes Public Offering Of Shares For US$1.2 Million 23
Curis Inc – Key Competitors 24
Curis Inc – Key Employees 25
Curis Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
May 03, 2018: Curis Reports First Quarter 2018 Financial Results 27
Mar 08, 2018: Curis Reports Fourth Quarter and Year-End 2017 Financial Results 29
Aug 03, 2017: Curis Reports Second Quarter 2017 Financial Results 31
May 04, 2017: Curis Reports First Quarter 2017 Financial Results 33
Mar 09, 2017: Curis Reports Fourth Quarter and Year-End 2016 Financial Results 35
Corporate Communications 38
Sep 24, 2018: Curis names James E. Dentzer as President and Chief Executive Officer 38
Apr 30, 2018: Cue Biopharma Announces Management Changes 39
Clinical Trials 40
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Curis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curis Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Curis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aurigene Discovery Enters into Agreement with Curis 10
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 12
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 14
Curis Enters into License Agreement with Guangzhou BeBetter Medicine 15
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 16
Curis Plans to Raise up to USD200 Million in Public Offering of Shares 17
Curis Plans to Raise up to USD23.6 Million in Public Offering of Shares 18
Curis Raises USD37 Million in Public Offering of Shares 19
Curis Raises USD69 Million in Public Offering of Shares 21
Curis Completes Public Offering Of Shares For US$1.2 Million 23
Curis Inc, Key Competitors 24
Curis Inc, Key Employees 25
Curis Inc, Subsidiaries 26

List of Figures
Curis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Curis Inc (CRIS):製薬・医療:M&Aディール及び事業提携情報(Curis Inc (CRIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆